EA202090558A1 - Схемы лечения - Google Patents

Схемы лечения

Info

Publication number
EA202090558A1
EA202090558A1 EA202090558A EA202090558A EA202090558A1 EA 202090558 A1 EA202090558 A1 EA 202090558A1 EA 202090558 A EA202090558 A EA 202090558A EA 202090558 A EA202090558 A EA 202090558A EA 202090558 A1 EA202090558 A1 EA 202090558A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
nuc
relates
cancer
methods
Prior art date
Application number
EA202090558A
Other languages
English (en)
Inventor
Хью Гриффит
Original Assignee
НУКАНА ПиЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by НУКАНА ПиЭлСи filed Critical НУКАНА ПиЭлСи
Publication of EA202090558A1 publication Critical patent/EA202090558A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90206—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G01N2333/91017—Methyltransferases (general) (2.1.1.) with definite EC number (2.1.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к 5-фтор-2'-дезоксиуридин-5'-О-[1-нафтил(бензокси-L-аланинил)]фосфату (NUC-3373) или его фармацевтически приемлемой соли для применения в лечении рака, в частности, путем внутривенной инфузии непрерывно в течение периода до 10 ч. Изобретение также относится к способам лечения рака путем введения NUC-3373 конкретным субпопуляциям больных раком. Изобретение также относится к способам выбора пациента для лечения препаратом NUC-3373.
EA202090558A 2017-08-30 2018-08-30 Схемы лечения EA202090558A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1713916.3A GB201713916D0 (en) 2017-08-30 2017-08-30 Treatment regimens
PCT/GB2018/052455 WO2019043392A1 (en) 2017-08-30 2018-08-30 TREATMENT DIAGRAMS

Publications (1)

Publication Number Publication Date
EA202090558A1 true EA202090558A1 (ru) 2020-06-15

Family

ID=60037308

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090558A EA202090558A1 (ru) 2017-08-30 2018-08-30 Схемы лечения

Country Status (16)

Country Link
US (2) US20200345755A1 (ru)
EP (1) EP3675823A1 (ru)
JP (2) JP2020531561A (ru)
KR (1) KR20200044829A (ru)
CN (1) CN111278427A (ru)
AU (1) AU2018326671B2 (ru)
BR (1) BR112020004119A2 (ru)
CA (1) CA3073649A1 (ru)
CL (1) CL2020000471A1 (ru)
EA (1) EA202090558A1 (ru)
GB (1) GB201713916D0 (ru)
IL (1) IL272738A (ru)
MX (1) MX2020002330A (ru)
PH (1) PH12020500374A1 (ru)
SG (1) SG11202001610QA (ru)
WO (1) WO2019043392A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62721B1 (sr) * 2011-03-01 2022-01-31 NuCana plc Farmaceutska formulacija koja sadrži fosforamidatni derivat 5-fluoro-2’-deoksiuridina za upotrebu u lečenju kancera
KR20180021697A (ko) * 2015-05-14 2018-03-05 뉴카나 피엘씨 암 치료
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives

Also Published As

Publication number Publication date
EP3675823A1 (en) 2020-07-08
US20200345755A1 (en) 2020-11-05
PH12020500374A1 (en) 2020-12-07
CN111278427A (zh) 2020-06-12
CL2020000471A1 (es) 2020-09-25
KR20200044829A (ko) 2020-04-29
AU2018326671A1 (en) 2020-04-02
JP2020531561A (ja) 2020-11-05
SG11202001610QA (en) 2020-03-30
CA3073649A1 (en) 2019-03-07
GB201713916D0 (en) 2017-10-11
JP2023096057A (ja) 2023-07-06
MX2020002330A (es) 2020-07-13
BR112020004119A2 (pt) 2020-09-01
AU2018326671B2 (en) 2023-11-30
IL272738A (en) 2020-04-30
WO2019043392A1 (en) 2019-03-07
US20240293439A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
MX2022004137A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
PH12020500374A1 (en) Treatment regimens
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2022009736A (es) Compuestos y metodos de p2x3 y/o p2x2/3.
MX2022000143A (es) Metodos novedosos.
TW201613589A (en) Combination methods for treating cancers
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX2021015352A (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal.
AU2018326364A1 (en) Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease
MX2019010695A (es) Compuesto antimicrobiano ((2r,3s,5r)-5-(4-amino-2-oxopirimidin-1(2 h)- il)-3-((butoxióxidofosfor-il)oxi) tetrahidrofuran-2-il)metil butil fosfato, y el uso del mismo en infecciones.
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
MX2022003585A (es) Metodos para tratar hiperfenilalaninemia.
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2017015664A (es) Administracion intravenosa de citrulina durante cirugia.
NZ771850A (en) Conjugates for use in methods of treating cancer
MX2020000118A (es) Composiciones y metodos para mejorar la funcion cardiaca.
EP4389218A3 (en) Composition for treating joint disease and kit containing same
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2019004200A (es) Terapia de combinacion.
MX2022003628A (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.